Tim Beyers

And it appears that Vivecart is positioning the capture.

Do I have this right, Carl?

50% market share in CIDP.

That is an extraordinary number.

Yes, but it does look like in Q1, there was a bit of seasonal insurance re-verification delays and increased Medicare Part D utilization leading to higher discounts, missing investor expectations.

So, the regulators aren't always friendly with this one.

Excellent.

Carl, you did it.

There's your first.

There's your first.

Now, we're going to go to the expert here.

Rick, Celsius, let's do it.

Yes, and I see this every day, Rick.

Every time I get on a bus or a train to commute into the office, I see at least one Celsius drink, not only on the way, but in the office where I end up going to work.

Celsius, no matter what we say about its growth rates, it is everywhere.

Yes, and the company's international division grew by 37% to 18.6 million.

That's including expansion into Canada, U.K., Ireland, Australia, New Zealand, and France.

So, successful global market penetration is happening.

Yes, but U.S.

revenue did plunge 33% year-over-year to $247 million.